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Abstract
Background
Cancer care including aggressive treatment procedures during the last phase of life in
patients with incurable cancer has increasingly come under scrutiny, while integrating spe-
cialist palliative care at an early stage is regarded as indication for high quality end-of-life
patient care.
Aim
To describe the demographic and clinical characteristics and the medical care provided at
the end of life of cancer patients who died in a German university hospital.
Methods
Retrospective cross-sectional study on the basis of anonymized hospital data for cancer
patients who died in the Munich University Hospital in 2014. Descriptive analysis and multi-
variate logistic regression analyses for factors influencing the administration of aggressive
treatment procedures at the end of life.
Results
Overall, 532 cancer patients died. Mean age was 66.8 years, 58.5% were men. 110/532
(20.7%) decedents had hematologic malignancies and 422/532 (79.3%) a solid tumor.
Patients underwent the following medical interventions in the last 7/30 days: chemother-
apy (7.7%/38.3%), radiotherapy (2.6%/6.4%), resuscitation (8.5%/10.5%), surgery
(15.2%/31.0%), renal replacement therapy (12.0%/16.9%), blood transfusions
(21.2%/39.5%), CT scan (33.8%/60.9%). In comparison to patients with solid tumors,
patients with hematologic malignancies were more likely to die in intensive care (25.4%
vs. 49.1%; p = 0.001), and were also more likely to receive blood transfusions (OR 2.21;
95% CI, 1.36 to 3.58; p = 0.001) and renal replacement therapy (OR 2.65; 95% CI, 1.49 to
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4.70; p = 0.001) in the last 7 days of life. Contact with the hospital palliative care team had
been initiated in 161/532 patients (30.3%). In 87/161 cases (54.0%), the contact was initi-
ated within the last week of the patient’s life.
Conclusions
Overambitious treatments are still reality at the end of life in cancer patients in hospital but
patients with solid tumors and hematologic malignancies have to be differentiated. More
efforts are necessary for the timely inclusion of specialist palliative care.
Introduction
Cancer is the second most frequent cause of death worldwide, after cardiovascular diseases.
According to estimates published by the International Agency for Research on Cancer
(IARC), there were 14.9 million new cases of cancer and 8.2 million deaths from cancer in
2012 [1].
Patients with advanced stages of cancer have a very high probability of spending the last
phase of their life in hospital and dying there [2–5]. Although patient surveys show that the
home environment is the preferred place of death, in reality hospital is by far the most frequent
location [6–8].
Physicians who treat patients in the last phase of their lives have to achieve a challenging
balance in relation to the appropriateness of the decisions they take with regard to medical
treatment. When is aggressive therapy justified towards the end of life, and when should atten-
tion turn towards palliative care? It is not an easy decision, and it is also made more difficult
by patients sometimes requesting intensive treatment measures even when the prognosis is
extremely limited [9,10].
The issue of what represents good care for cancer patients at the end of life is attracting
increasing interest in scientific research. Earle et al. approached the question by conducting a
literature review, focus group involvement, and expert discussions to define specific clinical
quality indicators for overtreatment, incorrect treatment, and undertreatment [11]. The indi-
cators identified were: 1) receiving chemotherapy in the last 14 days of life and/or start of che-
motherapy during the last 30 days of life (overtreatment); 2) more than one emergency
hospital admission and/or intensive-care unit admission during the last month of life (incor-
rect treatment); 3) involvement of hospice and/or specialized palliative services less than 3
days before death (undertreatment). In addition, benchmarking standards for aggressive treat-
ment at the end of life were defined—e.g., that cytostatic therapy should be administered
within the last 14 days of life in fewer than 10% of the patients treated [12].
In accordance with these criteria, studies have shown that the intensiveness of medical
treatments administered at the end of life has increased in recent years [13,14]. For example,
using data from 215,484 patients with statutory health insurance in the United States who
were over 65 years of age and died between 1991 and 2000, it has been shown that the propor-
tion of those who had still been receiving chemotherapy 14 days before they died rose from
9.7% in 1993 to 11.6% in 1999 [13]. Ho et al. [14] showed that in 227,161 adult cancer patients
who died in Ontario between 1993 and 2004, the percentage of patients who were still receiv-
ing chemotherapy within the last 14 days of their lives increased moderately from 2.02% to
2.88%. Increasing trends were also observed with regard to multiple emergency admissions
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(8.60% vs. 10.53%) and admission to an intensive care unit (3.06% vs. 5.39%) during the last
month of life.
Following the publication of the often-cited Temel study [15], clinical quality indicators
have gained importance internationally. Jennifer S. Temel and colleagues showed that includ-
ing early palliative care in the treatment of patients with metastatic non–small cell lung carci-
noma (NSCLC) not only improves their quality of life and reduces anxiety and depression, but
in addition leads to longer survival. Patients receiving additional palliative care received signif-
icantly fewer overambitious oncological treatments than other patients (33% vs. 54%;
p = 0.05).
On the basis of these results and those of other randomized studies on the topic of “early
integration of palliative care,” an expert committee in the American Society of Clinical Oncol-
ogy (ASCO) recommended that all patients with metastatic cancer and/or a high symptom
burden should be offered a combination of standard oncologic therapy and palliative care
[16]. Similar recommendations have been issued by the European Society of Medical Oncol-
ogy (ESMO) [17]. The following three statements regarding the time point at which palliative
care should be included were published in an evidence and consensus based German guideline
on palliative medicine for patients with incurable cancer [18]: 1) all patients with cancer should
receive information about palliative care, independent of the disease stage; 2) following diag-
nosis of incurable cancer, all patients should be offered palliative care, independently of
whether tumor-specific treatment is being administered; 3) specialist palliative care should be
integrated into oncological decision-making processes—e.g., through involvement in interdis-
ciplinary tumor conferences.
In Germany, 47% of the population dies in hospital and one in four citizens dies of cancer.
However, little is known about the care provided during the last phase of their lives for cancer
patients who die in hospital. The aim of this study was to describe the demographic and clini-
cal characteristics and medical care of cancer patients who died at a university hospital in
Germany.
Materials and methods
Study design
This retrospective cross-sectional study is based on hospital data for patients who died in the
Munich University Hospital of Ludwig Maximilian University, Germany, between January 1st
2014 and December 31st 2014. With more than 2,200 beds, Munich University Hospital—with
its 45 divisions, institutes, and departments in every field of medicine—is the second largest
maximum-care hospital in Germany.
Data source
Anonymized patient data from the hospital information system were analyzed. We received a
complete data set including information about age, gender, date of death, diagnosis, opera-
tions, procedures, and general in-hospital medical interventions, as well as the date of docu-
mentation. In addition, information about the place of death within the hospital was
evaluated.
Study population
The study population consisted of a subgroup of all patients who died at the university hospital
during the year 2014 (n = 1,222) and was exclusively related to deceased patients with a diag-
nosis of cancer (C00–C96) in accordance with version 10 of the International Classification of
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Diseases (ICD-10). In addition, cancer patients were divided into two sub-groups: a) patients
with a solid tumor (C00-C80) and b) patients with malignant neoplasms of lymphoid, hemato-
poietic and related tissue (C81-C96). This subdivision was made to consider cancer patients
more differentiated regarding their tumor-specific treatment options.
Operations, procedures, and medical interventions
In order to investigate whether overtreatment, incorrect treatment, or undertreatment
occurred in cancer patients at the end of their lives, code numbers from the Operationen-
und Prozedurenschlüssel (OPS)—the German version of the International Classification of
Procedures in Medicine (2013 version)—were extracted from the hospital information sys-
tem for the periods of the last 7 days and 30 days before the patient’s death and analyzed.
Chemotherapy was assumed to be present if OPS codes 8–541, 8–542, 8–543, 8–544, 8–546,
8–547, 8–549, or 6–00 in combination with code 8–54, were documented. The term “chemo-
therapy” included all classic types of cytostatic agent, hormones and hormone antagonists
used to treat cancer, immunotherapeutic agents used to treat cancer (monoclonal antibodies,
cytokines), and what are known as “small molecules” (e.g., tyrosine kinase inhibitors). The
following additional medical OPS codes were also analyzed: radiotherapy (8–520 to 8–526,
8–52a to 8–52d), resuscitation (8–771), any operations (5–01 to 5–99), tracheotomy (5–312),
percutaneous endoscopic gastrostomy (5–431.2), thoracentesis (8–152.2), ascites puncture
(8–153), extracorporeal membrane oxygenation (ECMO) (8–852.0 to 8–852.0a), renal
replacement therapy (8–853 to 8–857, 8–85a), blood cell transfusion (8–800 to 8–805), eryth-
rocyte transfusion (8–800.c), platelet transfusion (8–800.6, 8–800.d, 8–800.f, 8–800.g, 8.800.
h), blood plasma transfusion (8–810 to 8–812), tracheo-bronchoscopy (1–620), upper gastro-
intestinal endoscopy (1–630 to 1–638), computed tomography (CT) (3–20 to 3–24), and
magnetic resonance imaging (MRI) (3–80 to 3–84).
Palliative care service
The hospital palliative care team in the Department of Palliative Medicine at Munich Univer-
sity Hospital is a multiprofessional team that provides specialist palliative care for patients with
advanced disease and in the terminal phase in every ward in the hospital. This includes contin-
uous palliative consultation and collaborative treatment in patients with complex symptoms
and needs. The team consists of physicians, palliative care nurses, social workers, psycholo-
gists, a respiratory therapist and a permanent member of the hospital’s pastoral care service.
Via the hospital’s information system, the palliative care team can be called on by every spe-
cialist department in the hospital. The presence of the palliative care service is documented
using OPS code 8–982 (specialist complex palliative care). Cases in which this code was docu-
mented were recorded and statistically analyzed.
Statistical analyses
The recorded frequencies of clinical characteristics, operations, medical procedures and con-
tact with the hospital palliative care team were presented in absolute and percentage figures.
Calculations were carried out for the complete group of all cancer patients who died
(C00-C96) and also for deceased patients with solid tumors (C00-C80) as well as for patients
with hematological malignancies (C81-C96). We also separated cancer patients with chemo-
therapy at the end of life and performed a stratified analysis according to sepsis status and
tumor entity (C00-C96). Sepsis was classified according to the ICD-10 codes B37.7, A39.2,
A39.4, A40, A41, and R57.2.
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Differences between the sub-groups were tested. Continuous data were tested for normal
distribution using the Kolmogorov–Smirnov test, and were analyzed with the unpaired t-test if
normally distributed. If a normal distribution was not present, the nonparametric Wilcoxon–
Mann–Whitney test was used. The chi-squared test was used for categorical data, and in cases
of low frequency, Fisher’s exact test with cell count less than five was used. The significance
level was set at p< 0.05. To take into account the global increase in the likelihood of alpha
error (type 1 error) with multiple testing in the same sample, the alpha level was corrected
using the Holm–Bonferroni procedure. Using multivariate logistic regression, the influences
of age (< 60 years (1) vs. 60 years (0)), gender (men (1) vs. women (0)), the time interval
since first diagnosis of cancer (< 6 months (1) vs. 6 months (0)), and tumor entity (hemato-
logical malignancies (1) vs. solid (0) tumors) were investigated relative to the implementation
of resuscitation measures, surgery of whatever sort, renal replacement procedures, and blood
transfusions 1 month and 1 week before the death of the cancer patient. Odds ratios (OR) and
95% confidence intervals (CI) were calculated. The two-sided Wald statistic was used to test
significance. Log likelihood (–2LL) and Nagelkerke’s pseudo-R2 coefficient were used to evalu-
ate the quality of the multivariate model. The analyses were carried out using the IBM SPSS
Statistics program, version 23.
Ethics approval
The study was submitted to the University of Munich’s ethics committee and obtained ethics
approval (ref. no. 443–15 UE). Due to the anonymized analysis of the data, consultation with
the ethics committee, albeit it was carried out, was not an absolute requirement.
Results
A total of 532/1222 patients (43.5%) died of cancer during 2014. Of these patients, 422/532
(79.3%) had a solid tumor and 110/532 (20.3%) a malignant neoplasm of lymphoid, hemato-
poietic and related tissue. Malignant tumors of the gastrointestinal tract (C15-C26) were most
frequent (29.3%). One in ten patients died of a malignant neoplasm of the respiratory tract
(C30-C39) (Fig 1).
There were slightly more males than females among the cases of death. The mean age at
death was 66.8 years. In one-third of the patients, the first diagnosis of cancer had been less
than 6 months ago. In patients with solid malignant tumors, a secondary malignant neoplasm
was documented in at least 62.1%. A bone marrow transplant was performed in one-fifth of
patients with hematological malignancy (Table 1).
Places of death in the hospital were distributed as follows (all cancer patients, N = 532): reg-
ular ward, n = 196 (36.8%); palliative care unit, n = 171 (32.1%); intermediate care or intensive
care unit, n = 161 (30.3%); and other, n = 4 (0.8%). Compared to patients with solid tumors,
patients with hematological malignancies died in an intermediate care or intensive care unit
more often (25.4% vs. 49.1%, p = 0.001), and less often in a palliative care unit (36.7% vs.
14.5%, p = 0.001) (Fig 2).
Chemotherapy had been administered within the last week of life in 41/532 cancer patients
(7.7%) and within the last 30 days of life in 204/532 patients (38.3%). Approximately every 5th
patient with a malignant tumor of the lymphatic or hematopoietic tissue and every 20th patient
with a solid tumor received chemotherapy within the last week. In addition, 77/110 patients
with hematological malignancy (70.0%) and 127/422 patients with a solid tumor (30.1%)
received tumor-specific therapy during the last month. Only a small percentage of patients
received radiotherapy during the last week of life (2.6%) or last month of life (6.4%). One in
ten cancer patients underwent resuscitation at the end of life. The proportions were 8.5% (last
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week) and 10.5% (last month). In comparison with patients with solid tumors, patients with
hematological malignancies were more likely to receive blood transfusions (18.5% vs. 31.8%;
p = 0.002), platelet transfusions (5.0% vs. 19.1%; p = 0.001) and renal replacement therapy
(9.7% vs. 20.9%; p = 0.001) during their last week of life. The prevalence figures for these proce-
dures in the last month of life were 32.7% vs. 65.5% (p = 0.001), 9.2% vs. 48.2% (p = 0.001) and
13.0% vs. 31.8% (p = 0.001), respectively. With regard to diagnostic measures at the end of life
(last week/month), trachea-bronchoscopy procedures were carried out in 4.5%/9.0%, endos-
copy of the upper GI tract in 7.7%/13.5%, magnetic resonance imaging (MRI) in 2.8%/10.5%
and computed tomography (CT) in 33.8%/60.9% (Tables 2 and 3).
Patients with malignant neoplasms of respiratory and intrathoracic organs (C30-C39) were
most likely to receive chemotherapy in the last 7 days compared to patients with other malig-
nant solid tumors. In patients with ICD-10 codes C00-C14, C15-C26, C45-C49 and C51-C58,
surgery was most frequently performed during the last 30 days. Patients with neoplasms of lip,
oral cavity and pharynx received tracheotomy in 12.5% of cases in the last month and in 4.2%
of cases in the last week. More than one-fifth of all patients with tumor of the urinary tract
were treated with renal replacement therapy (Tables 4 and 5).
Patients with hematological malignancies were more likely to develop septic complications
after chemotherapy compared to patients with malignant solid tumors. The corresponding fre-
quencies were 68.8% versus 31.3% (last 7 days) and 64.9% versus 35.1% (last 30 days), respec-
tively (Tables 6 and 7).
Tumor entity and time of first diagnosis were significantly associated with therapeutic mea-
sures being administered at the end of life (resuscitation, surgery, renal replacement
Fig 1. The distribution of the tumor entity of deceased cancer patients (N = 532). C00-C14: Malignant neoplasms of lip, oral cavity and pharynx,
C15-C26: Malignant neoplasms of digestive organs, C30-C39: Malignant neoplasms of respiratory and intrathoracic organs, C40-C41: Malignant
neoplasms of bone and articular cartilage, C43-C44, Melanoma and other malignant neoplasms of skin, C45-C49: Malignant neoplasms of mesothelial
and soft tissue, C50: Malignant neoplasms of breast, C51-C58: Malignant neoplasms of female genital organs, C60-C63: Malignant neoplasms of male
genital organs, C64-C68: Malignant neoplasms of urinary tract, C69-C72: Malignant neoplasms of eye, brain and other parts of central nervous system,
C73-C75: Malignant neoplasms of thyroid and other endocrine glands, C76-C80: Malignant neoplasms of ill-defined, other secondary and unspecified
sites, C81-C96: Malignant neoplasms of lymphoid, hematopoietic and related tissue.
https://doi.org/10.1371/journal.pone.0175124.g001
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procedures, blood cell transfusions). For example, the probability of receiving renal replace-
ment procedures in the last phase of life (week/month) among patients with hematological
malignancies was increased in comparison with patients with solid malignant tumors (OR
2.65; 95% CI, 1.49 to 4.70; p = 0.001 / OR 3.47; 95% CI, 2.09 to 5.75; p = 0.001). A markedly
Table 1. Characteristics of deceased cancer patients.
All cancer patients Solid tumor Hematological
malignancy
N = 532 N = 422 N = 110
n (%) n (%) n (%) P
Gender
Female 219 (41.2) 169 (40.0) 50 (45.5)
Male 313 (58.8) 253 (60.0) 60 (54.5) 0.305
Age
Mean (SD) 66.8 (14.8) 67.0 (14.0) 65.8 (17.8) 0.435
< 40 years 25 (4.7) 17 (4.0) 8 (7.3) 0.152
40–59 years 104 (19.5) 88 (20.9) 16 (14.5) 0.137
60–79 years 326 (61.3) 257 (60.9) 69 (62.7) 0.726
 80 years 77 (14.5) 60 (14.2) 17 (15.5) 0.743
Duration between diagnosis and cancer death*
< 6 months 173 (33.6) 140 (34.5) 33 (30.5) 0.527
6–12 months 73 (14.2) 52 (12.8) 21 (19.5) 0.066
 12 months 268 (52.2) 214 (52.7) 54 (50.0) 0.762
Malignant solid tumors (ICD-10; C00-C80)
Secondary malignant neoplasm (ICD-10; C77 or C78 or C79) 262 (62.1)
- Lymph nodes (ICD-10; C77) 101 (23.9)
- Respiratory and digestive organs (ICD-10; C78) 195 (46.2)
- Other and unspecified sites (ICD-10; C79) 145 (34.4)
- Only lymph nodes (ICD-10; C77) 13 (3.1)
- Only respiratory and digestive organs (ICD-10; C78) 72 (17.1)
- Other and unspecified sites (C79) 37 (8.8)
- ICD-10; C77 and C78 32 (7.6)
- ICD-10; C77 and C79 17 (4.0)
- ICD-10; C78 and C79 52 (12.3)
- ICD-10; C77 and C78 and C79 39 (9.2)
Malignant neoplasms of lymphoid, hematopoietic and related tissue (ICD-10; C81-C96)
Bone morrow transplant status (ICD-10; Z94.80 or Z94.81) 22 (20.0)
Not having achieved remission# 61 (55.5)
- Malignant immunproliferative diseases, certain B-cell lymphomas (C88.00, C88.20, C88.30, C88.40, C88.70) 0 (0.0)
- Multiple myeloma and malignant plasma cell neoplasms (C90.0, C90.10, C90.20, C90.30) 18 (16.4)
- Lymphoid leukemia (C91.00, C91.10, C91.30, C91.40, C91.50, C91.60, C91.70, C91.80, C91.90) 11 (10.0)
- Myeloid leukemia (C92.00, C92.10, C92.20, C92.30, C92.40, C92.50, C92.60, C92.70, C92.80, C92.90) 30 (27.3)
- Monocytic leukemia (C93.00, C93.30, C93.70, C93.90) 1 (0.9)
- Other leukemias of specific cell types (C94.00, C94.20, C94.30, C94.40, C94.60, C94.70, C94.8) 2 (1.8)
- Leukemia of unspecified cell type (C95.00, C95.10, C95.70, C95.8, C95.90) 1 (0.9)
* N = 514 all cancer patients; n = 406 patients with solid tumors, n = 108 patients with hematological malignancies.
# ICD-10; C88.00, C88.20, C88.30, C88.40, C88.70, C88.90, C90.0, C90.10, C90.20, C90.30, C91.00, C91.10, C91.30, C91.40, C91.50, C91.60, C91.70,
C91.80, C91.90, C92.00, C92.10, C92.20, C92.30, C92.40, C92.50, C92.60, C92.70, C92.80, C92.90, C93.00, C93.30, C93.70, C93.90, C94.00, C94.20,
C94.30, C94.40, C94.60, C94.70, C94.8, C95.00, C95.10, C95.70, C95.8, C95.90.
https://doi.org/10.1371/journal.pone.0175124.t001
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Fig 2. Place of death in hospital for cancer patients. IMC = Intermediate Care Unit; ICU = Intensive Care Unit.
https://doi.org/10.1371/journal.pone.0175124.g002
Table 2. Frequencies of medical procedures in cancer patients with malignant solid tumors compared to non-solid tumors in the last week of life.
All cancer patients Solid tumor Hematological
malignancy
N = 532 N = 422 N = 110
n (%) n (%) n (%) P
Chemotherapy 41 7.7 21 5.0 20 18.2 0.001
Radiotherapy 14 2.6 11 2.6 3 2.7 0.944
Resuscitation 45 8.5 34 8.1 11 10.0 0.514
Surgery 81 15.2 67 15.9 14 12.7 0.413
Tracheotomy 3 0.6 2 0.5 1 0.9 0.502
PEG tube placement 2 0.4 2 0.5 0 0.0 -
Pleural puncture 18 3.4 13 3.1 5 4.5 0.552
Ascites puncture 5 0.9 4 0.9 1 0.9 1.000
Extracorporeal membrane oxygenation 1 0.2 0 0.0 1 0.9 -
Renal replacement therapy 64 12.0 41 9.7 23 20.9 0.001
Blood cell transfusion 113 21.2 78 18.5 35 31.8 0.002
Erythrocyte transfusion 92 17.3 71 16.8 21 19.1 0.576
Platelet transfusion 42 7.9 21 5.0 21 19.1 0.001
Blood plasma transfusion 63 11.8 50 11.8 13 11.8 1.000
Tracheo-bronchoscopy 24 4.5 16 3.8 8 7.3 0.117
Endoscopy of upper GI tract 41 7.7 38 9.0 3 2.7 0.027
Computed tomography (CT) 180 33.8 141 33.4 39 35.5 0.687
Magnetic Resonance Imaging (MRI) 15 2.8 11 2.6 4 3.6 0.525
https://doi.org/10.1371/journal.pone.0175124.t002
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increased likelihood of transfusion of blood products was also observed (OR 2.21; 95% CI, 1.36
to 3.58; p = 0.001 / OR 4.48; 95% CI, 2.83 to 7.12; p = 0.001) (Table 8).
Only 161/532 cancer patients (30.3%) had been in contact with the palliative care team
before death. Among patients with a solid tumor, one in three (143/422) received palliative
care (33.9%). Contact with the palliative care team had only been established in 18/110 patients
with a hematological malignancy (16.4%), (Fig 3).
In 87/161 cases (54.0%), the inpatient hospital palliative care team was contacted within the
last week of the patient’s life. In only 6.2% of the cases, the interval between first contact and
death was longer than 20 days.
The duration of care of the hospital palliative care team was most often between 1 to 3 days
(40.4%). One in five patients (34/161) received a period of care for more than 7 days. The
length of care did not differ between cancer patients with solid tumors and patients with hema-
tological malignancies (Table 9).
Discussion
This study describes the intensity of care provided to cancer patients who spent their final
phase of life in a university hospital in Germany and died there. In general, intensive medical
interventions, including life-prolonging treatments, were carried out frequently during the last
phase of life. However, the intensity of medical care was associated with tumor entity. Patients
with a malignant tumor of the lymphatic or hematopoietic tissue received more often intensive
therapy and were more likely to die in an intensive care unit. Palliative medical expertise was
only integrated into care in one third of all deceased cancer patients, often only in the very last
days of life.
Table 3. Frequencies of medical procedures in cancer patients with malignant solid tumors compared to non-solid tumors in the last month of
life.
All cancer patients Solid tumor Hematological
malignancy
N = 532 N = 422 N = 110
n (%) n (%) n (%) P
Chemotherapy 204 38.3 127 30.1 77 70.0 0.001
Radiotherapy 34 6.4 28 6.6 6 5.5 0.652
Resuscitation 56 10.5 43 10.2 13 11.8 0.620
Surgery 165 31.0 134 31.8 31 28.2 0.471
Tracheotomy 18 3.4 12 2.8 6 5.5 0.177
PEG tube placement 5 0.9 4 0.9 1 0.9 0.970
Pleural puncture 22 4.1 14 3.3 8 7.3 0.064
Ascites puncture 32 6.0 29 6.9 3 2.7 0.103
Extracorporeal membrane oxygenation 6 1.1 2 0.5 4 3.6 0.019
Renal replacement therapy 90 16.9 55 13.0 35 31.8 0.001
Blood cell transfusion 210 39.5 138 32.7 72 65.5 0.001
Erythrocyte transfusion 194 36.5 130 30.8 64 58.2 0.001
Platelet transfusion 92 17.3 39 9.2 53 48.2 0.001
Blood plasma transfusion 100 18.8 72 17.1 28 25.5 0.045
Tracheo-bronchoscopy 48 9.0 29 6.9 19 17.3 0.001
Endoscopy of upper GI tract 72 13.5 64 15.2 8 7.3 0.031
Computed tomography (CT) 324 60.9 246 58.3 78 70.9 0.016
Magnetic Resonance Imaging (MRI) 56 10.5 44 10.4 12 10.9 0.883
https://doi.org/10.1371/journal.pone.0175124.t003
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The study included patients in a university hospital that is required to ensure medical care
at the highest medical level and to incorporate research and teaching into patient care in inno-
vative ways. In the area of care for patients at the end of their lives, this standard also involves a
risk that medical interventions may be initiated or continued even when the expected outcome
is futile, and that insufficient consideration may be given for stopping or withdrawing
treatment.
For patients with solid tumors, our results partially meet the intended benchmarking stan-
dards of the Earle criteria, meaning that the proportion of patients receiving chemotherapy in
the last 14 days of life should be lower than 10%. Our data relate to the last 7 and not 14 days of
life. We used the shorter time span as it is more likely to foresee dying within a week before
death and to illustrate potential overtreatment towards the end of life more clearly.
Our reported frequencies are consistent with the international literature, in which treat-
ment periods of two weeks or one month before death are usually reported, with period preva-
lence figures during the last 14 days of between 2.02% and 22.5% and during the last 30 days of
between 9.0% and 43.0% [13, 14, 19–33].
The role of chemotherapy in solid tumors at the end of life is regarded increasingly criti-
cally. Its life-prolonging effect is usually slight, and there is a risk of reducing the patient’s qual-
ity of life and even lifespan. In a study including cancer patients with very advanced tumor
stages who received palliative chemotherapy, Prigerson et al. [34] found that patients with
good functional status (ECOG score 1) had a poorer quality of life with treatment, while in
patients with a moderate or poor functional status (ECOG score 2–3), quality of life was
unchanged. Otherwise, it is evident that tumor-specific drugs used in recent years are more
effective with fewer side effects. A life-prolonging effect amounting to several months has been
Table 6. Cancer patients with chemotherapy treatment in the last week of life—frequencies of sepsis stratified by tumor entity.
Chemotherapy
within the last 7
days
No sepsis Sepsis*
N = 41 N = 25 N = 16
n (%) n (%) n (%) P
Solid tumors (ICD-10; C00-C80) 21 51.2 16 64.0 5 31.3 0.041
- lip, oral cavity, pharynx (C00-C14) 2 4.9 2 8.0 0 0.0 -
- digestive organs (C15-C26) 4 9.8 2 8.0 2 12.5 0.637
- respiratory and intrathoracic organs (C30-C39) 8 19.5 7 28.0 1 6.3 0.086
- bone and articular cartilage (C40-C41) 0 0.0 0 0.0 0 0.0 -
- skin (C43-C44) 1 2.4 1 4.0 0 0.0 -
- mesothelial and soft tissue (C45-C49) 1 2.4 1 4.0 0 0.0 -
- breast (C50) 0 0.0 0 0.0 0 0.0 -
- female genital organs (C51-C58) 3 1.9 2 2.8 1 1.1 0.587
- male genital organs (C60-C63) 3 1.9 1 1.4 2 2.2 0.998
- urinary tract (C64-C68) 14 8.7 3 4.2 11 12.4 0.092
- eye, brain and other parts of CNS (C69-C72) 4 2.5 3 4.2 1 1.1 0.326
- thyroid and other endocrine glands (C73-C75) 1 0.6 0 0.0 1 1.1 -
- other secondary and unspecified sites (C76-C80) 3 1.9 1 1.4 2 2.2 0.998
Lymphoid, hematopoietic and related tissue (ICD-10;C81-C96) 20 48.8 9 36.0 11 68.8 0.041
- bone marrow transplant status 4 9.8 0 0.0 4 25.0 -
- not having achieved remission 12 29.3 5 20.0 7 43.8 0.103
* ICD-10: B37.7, A39.2, A39.4, A40, A41, R57.2; CNS = central nervous system
https://doi.org/10.1371/journal.pone.0175124.t006
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demonstrated even in patients with solid tumors such as lung, prostate, and colon carcinoma.
In addition, palliative chemotherapy can also contribute to an improvement in the quality of
life [35,36]. Unfortunately, the prognosis for the course of treatment cannot always be suffi-
ciently well assessed, whether due to comorbidity, complications during current chemother-
apy, or the disease progression so that the possibility of a sudden deterioration in the patient’s
physical condition during treatment always has to be taken into account. It is often patients
themselves who request oncological treatment, despite a hopeless disease situation and an
unfavorable risk–benefit ratio. Chu et al. [9] clearly showed that patients with advanced, incur-
able cancer often aim to achieve the maximum gain in life expectancy while accepting a high
level of toxicity. Slevin et al. [10] showed that cancer patients were willing to undergo burden-
some chemotherapy even when the likelihood of a cure was only 1%.
In our study, the majority of those who received chemotherapy were patients with malig-
nant neoplasia in the lymphatic and hematopoietic tissue. Nearly one in two patients who had
received cytostatic treatment during the last 7 days of life and one in three patients who had
received chemotherapy during the last 30 days of life belonged to this group. In hematological
patients, for example, with acute leukemia, a curative outcome is often intended with intensive
and aggressive treatment in primary therapy, and even with advanced disease, these patients
can still benefit from available oncological treatments. From this point of view, the data should
be interpreted cautiously with regard to overtreatment at the end of life. Especially as the Earle
criteria are based on data from patients dying from lung, breast, colorectal, or other gastroin-
testinal cancers [12]. Therefore, it can be questioned if they are applicable to hematological
malignancies. Furthermore, patients with malignant neoplasms of lymphoid, hematopoietic
and related tissue often require intensive-care unit (ICU) admission due to organ failure
Table 7. Cancer patients with chemotherapy treatment in the last month of life—frequencies of sepsis stratified by tumor entity.
Chemotherapy within
the last 30 days
No sepsis Sepsis*
N = 204 N = 147 N = 57
n (%) n (%) n (%) P
Solid tumors (C00-C80) 127 62.3 107 72.8 20 35.1 0.001
- lip, oral cavity, pharynx (C00-C14) 4 2.0 4 2.7 0 0.0 -
- digestive organs (C15-C26) 45 22.1 34 23.1 11 19.3 0.554
- respiratory and intrathoracic organs (C30-C39) 30 14.7 29 19.7 1 1.8 0.001
- bone and articular cartilage (C40-C41) 0 0.0 0 0.0 0 0.0 -
- skin (C43-C44) 3 1.5 3 2.0 0 0.0 -
- mesothelial and soft tissue (C45-C49) 4 2.0 4 2.7 0 0.0 -
- breast (C50) 13 6.4 11 7.5 2 3.5 0.523
- female genital organs (C51-C58) 8 3.9 8 5.4 0 0.0 -
- male genital organs (C60-C63) 1 0.5 0 0.0 1 1.8 -
- urinary tract (C64-C68) 7 3.4 6 4.1 1 1.8 0.676
- eye, brain and other parts of CNS (C69-C72) 4 2.0 3 2.0 1 1.8 1.000
- thyroid and other endocrine glands (C73-C75) 5 2.5 3 2.0 2 3.5 0.620
- other secondary and unspecified sites (C76-C80) 3 1.5 2 1.4 1 1.8 1.000
Lymphoid, hematopoietic and related tissue (C81-C96) 77 37.7 40 27.2 37 64.9 0.001
- bone marrow transplant status 17 8.3 3 2.0 14 24.6 0.001
- not having achieved remission 45 22.1 21 14.3 24 42.1 0.001
* ICD-10: B37.7, A39.2, A39.4, A40, A41, R57.2; CNS = central nervous system
https://doi.org/10.1371/journal.pone.0175124.t007
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through disease progression or treatment-related complications. The most common reasons
for ICU admission in this population include sepsis and respiratory failure. Mortality in
patients with hematologic malignancy admitted to ICU varies from 33% to 69% in some stud-
ies [37,38]. We observed that more than the half of these patients with chemotherapy treat-
ment developed septic complications and died mostly in the intensive care unit. Patients with
hematological malignancies were more likely than those with solid tumors to have erythrocyte
transfusion, platelet transfusion, blood plasma transfusion, renal replacement therapy and
extracorporeal membrane oxygenation in the last 30 days of life. In consequence, diagnostic
measures were also used more widely in this patient group illustrating the strong motivation of
physicians to treat the underlying disease as long as possible. Unfortunately, this disease-spe-
cific focus hindered specialist palliative care involvement as demonstrated in less contact to
the hospital palliative care team and less frequent admissions and deaths on the palliative care
unit. This is consistent with a meta-analysis of 16 studies from various countries demonstrat-
ing that hematology patients were more likely to die in hospital [39] and other population-
based studies that reported poorer quality of end-of-life care among hematologic patients
[14,40,41].
The current study showed that about one in ten cancer patients underwent resuscitation
during their last month of life. Little is known about the prevalence of resuscitation in cancer
Table 8. Factors associated with aggressive cancer care at the end of life.
Resuscitation Surgery
OR 95% CI P OR 95% CI P
Last 7 days
Gender: male (1) vs. female (0) 0.73 0.39–1.36 0.320 0.72 0.44–1.17 0.184
Age: < 60 (1) vs. 60 (0) years 0.68 0.31–1.53 0.352 1.06 0.60–1.85 0.846
Initial diagnosis: < 6 (1) vs. 6 (0) months 2.13 1.14–3.95 0.017 2.00 1.23–3.25 0.005
Cancer type: hematological malignancy (1) vs. solid (0) tumor 1.27 0.62–2.61 0.523 0.77 0.41–1.44 0.415
Goodness of fit (– 2 log likelihood/Nagelkerke’s R2) 300.482/0.033 444.225/0.031
Last 30 days
Gender: male (1) vs. female (0) 0.70 0.40–1.23 0.216 1.16 0.79–1.71 0.447
Age: < 60 (1) vs. 60 (0) years 0.96 0.49–1.87 0.904 1.24 0.80–1.92 0.346
Initial diagnosis: < 6 (1) vs. 6 (0) months 1.83 1.04–3.23 0.036 2.40 1.63–3.53 0.001
Cancer type: hematological malignancy (1) vs. solid (0) tumor 1.19 0.61–2.29 0.630 0.88 0.55–1.41 0.584
Goodness of fit (– 2 log likelihood/Nagelkerke’s R2) 352.199/0.022 637.680/0.055
Renal replacement therapy Blood cell transfusion
OR 95% CI P OR 95% CI P
Last 7 days
Gender: male (1) vs. female (0) 1.51 0.85–2.67 0.157 0.99 0.64–1.54 0.982
Age: < 60 (1) vs. 60 (0) years 0.81 0.41–1.59 0.535 1.42 0.87–2.32 0.165
Initial diagnosis: < 6 (1) vs. 6 (0) months 2.19 1.28–3.76 0.004 2.48 1.64–3.84 0.001
Cancer type: hematological malignancy (1) vs. solid (0) tumor 2.65 1.49–4.70 0.001 2.21 1.36–3.58 0.001
Goodness of fit (– 2 log likelihood/Nagelkerke’s R2) 370.489/0.073 524.063/0.074
Last 30 days
Gender: male (1) vs. female (0) 1.93 1.16–3.22 0.011 1.17 0.80–1.71 0.434
Age: < 60 (1) vs. 60 (0) years 1.14 0.65–1.99 0.653 1.83 1.18–2.82 0.007
Initial diagnosis: < 6 (1) vs. 6 (0) months 1.97 1.22–3.18 0.006 2.63 1.77–3.91 0.001
Cancer type: hematological malignancy (1) vs. solid (0) tumor 3.47 2.09–5.75 0.001 4.48 2.83–7.12 0.001
Goodness of fit (– 2 log likelihood/Nagelkerke’s R2) 449.641/0.104 646.195/0.161
https://doi.org/10.1371/journal.pone.0175124.t008
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patients at the end of life. In a Taiwanese study, 5-year prevalence rate of 10.5% in cancer
patients was reported [42]. Young, male, unmarried individuals and patients with underlying
malignant hematological conditions, or non-metastatic tumor stages, as well those with as a
recent diagnosis, were predisposed to undergo resuscitation. Only 6.2% of cancer patients are
able to leave the hospital after successful in-hospital resuscitation [43]. We could not assess
whether any “do not resuscitate” (DNR) orders were applied to individual patients. Literature
Fig 3. Frequency of patients’ contact with the hospital palliative care team.
https://doi.org/10.1371/journal.pone.0175124.g003
Table 9. Cancer patients, who had contact with the hospital palliative care team before death.
All cancer patients Solid tumor Hematological
malignancy
N = 161 N = 143 N = 18
n %, (%)* n %, (%)* n %, (%)* P
Time between initial patient contact with the hospital palliative care team and the patient’s death
< 24 hours 9 5.6 (5.6) 7 4.9 (4.9) 2 11.1 (11.1) 0.265
1–2 days 28 17.4 (23.0) 25 17.5 (22.4) 3 16.7 (27.8) 1.000
3–4 days 24 14.9 (37.9) 19 13.3 (35.7) 5 27.8 (55.6) 0.151
5–7 days 26 16.1 (54.0) 23 16.1 (51.8) 3 16.7 (72.3) 1.000
8–13 days 40 24.9 (78.9) 37 25.8 (77.6) 3 16.7 (89.0) 0.565
14–20 days 24 14.9 (93.8) 23 16.1 (93.7) 1 5.5 (94.5) 0.479
 21 days 10 6.2 (100) 9 6.3 (100) 1 5.5 (100) 1.000
Duration of care of the hospital palliative care team
< 24 hours 19 11.8 (11.8) 17 11.9 (11.9) 2 11.1 (11.1) 1.000
1–3 days 65 40.4 (52.2) 57 39.9 (51.8) 8 44.4 (55.5) 0.709
4–7 days 43 26.7 (78.9) 38 26.6 (78.4) 5 27.8 (83.3) 0.913
8–13 days 27 16.8 (95.7) 24 16.8 (95.2) 3 16.7 (100) 1.000
 14 days 7 4.3 (100) 7 4.8 (100) 0 0.0 (100) -
* Cumulative percentage
https://doi.org/10.1371/journal.pone.0175124.t009
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data show that a DNR order is usually only arranged and recorded in writing very shortly
before death [44] and that the omission of resuscitation measures is not discussed frequently
with patients [45].
Patients with malignant diseases often suffer from physical symptoms and stressful psycho-
social situations—not only in very advanced situations or when they are near death, but
already earlier in the disease trajectory. The need for early integration of palliative care into the
treatment of patients with incurable cancer and the wide-ranging benefits is nowadays uncon-
troversial and well supported by evidence [15, 46–55]. Early integration of palliative care leads
to reduced burden of physical and mental symptoms, fewer hospital admissions, shorter hospi-
talization periods, improved perception of the disease prognosis among patients, larger num-
bers of transfers to a hospice, longer hospice stays, and fewer aggressive treatment procedures
at the end of life. In general, this leads to better quality of life of patients and families and
greater acceptance of the disease situation. In addition, cost reductions in the health care sector
are also a possible result [56–61]. The term “early integration” is widely used and normally
seen as months to years before death without a clear timeframe. The German Palliative Care
Guidelines suggest to involve palliative care at the diagnoses of the incurability of an oncologi-
cal disease [18]. Others have suggested to define entity specific stages for every type of cancer
[62].
In our study only one-third of the cancer patients who died received support from the palli-
ative care team during their hospital treatment, more than half of them only in the last week of
life. The time interval between first contact with the palliative service and the patient’s death
was longer than 3 weeks only in a minority of patients. Early integration of palliative care in
the course of treatment thus hardly took place.
In everyday clinical work, the decision to include palliative care mainly depends on the phy-
sician primarily treating the patient and the inclusion of a palliative care team does not appear
expedient to all oncologists [63]. The term “palliative care” is often misunderstood as terminal
care only [64]. Some physicians also believe that merely mentioning the term “palliative medi-
cine” will deprive the patient of any hope and that the term is associated with the stigma of
death. In that view, including a palliative care team in patient care would simply represent an
additional burden for the patient [65]. There are also barriers to the introduction of systematic
outcome measurements that would document patients’ needs and the effectiveness of palliative
medical interventions [66].
What opportunities are available for integrating palliative care into in-patient oncological
care structures? Conceivable approaches might be, for example: an obligatory consultation
with a palliative care physician or specialist about the palliative services available, at the time
when the cancer is diagnosed or when an incurable tumor stage is reached; joint visits by
oncologists and palliative care specialists to the oncology ward; recognizing and registering
patients with palliative care needs in a timely fashion by trained medical and nursing staff
(with a palliative care representative) in every treatment setting (emergency department, out-
patient oncology department, general ward, intensive-care unit); and inclusion of a palliative
physician or medical/nursing palliative specialist in tumor conferences. More detailed and spe-
cific information about palliative medicine and communicative skills should also be provided
during basic training for physicians and nurses, to ensure that well-informed patients are able
to clarify any open questions at an early stage for the purposes of forward-looking health care
planning, able to correctly assess the prognosis for the cancer, and able to express their wishes
for the last phase of life. These targets should be included in the specialist societies’ guidelines
and in the criteria for certification of specialist oncology centers, and they should be regularly
audited. Last but not least, the financial basis and facilities for charging the corresponding
costs need to be established in order to ensure that such structures become sustainable.
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Limitations
The study is based on anonymized patient data. Accordingly, there was no information avail-
able on factors that might have influenced the use of aggressive treatment procedures at the
end of life, such as the patient’s general physical condition, comorbidity, tumor stage, treat-
ment approach (curative or palliative), type of chemotherapy, complications during the course
of disease, patient’s treatment preferences, and medical instruction to limit treatment (e.g., do
not resuscitate, DNR). In this context, it was not possible to draw any conclusions regarding
the reasons for intensified treatment measures being administered at the end of life. The study
was limited to deceased cancer patients. It can be assumed that these patients were mainly at a
very advanced stage of the disease at the time when the data were collected. Patients with
early-stage cancers may accordingly have been underrepresented, so that early integration of
the in-patient palliative service into the course of oncological treatment might be assessed too
conservatively.
Conclusions
At the end of their lives, cancer patients receive a large number of therapeutic and diagnostic
procedures. Early integration of specialist palliative care to oncological treatment might help
reduce the level of potential overtreatment. Sufficient structures and concepts have to be devel-
oped and implemented to improve patient care in acute hospitals.
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